Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Losartan · Arbli

Small molecule · Antagonist of Angiotensin II receptor type 1 (AGTR1) · developed by Scienture

Approved FDA, Mar 2025
1 Registered trials

What is Losartan?

Losartan is a non-peptide angiotensin II receptor antagonist that selectively blocks AT1 receptors in vascular smooth muscle and the adrenal gland. It inhibits the vasoconstricting and aldosterone-secreting effects of angiotensin II, lowering blood pressure.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Arbli, Cozaar
Drug type
Small molecule
Targets
Angiotensin II receptor type 1 (AGTR1)
Mechanism
Antagonist of Angiotensin II receptor type 1 (AGTR1)
Pathways
vasoconstriction, aldosterone secretion
Therapy area
Cardiovascular, Endocrine
Developer
Scienture
In trials of
ACTU
FDA status
Approved as Arbli (March 13, 2025), NDA218772 · FDA label

✅ FDA-approved uses

From the indications section of the FDA label (version of Oct 3, 2025). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05077800 Phase 2 Pancreatic Adenocarcinoma Active not recruiting ACTU

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Pancreatic AdenocarcinomaPancreatic Adenocarcinoma Metastatic

Other drugs acting on AGTR1

Olmesartan FDA approved

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.